<DOC>
	<DOCNO>NCT00659971</DOCNO>
	<brief_summary>The purpose study determine optimal dose PAC113 mouthrinse treatment oral candidiasis HIV seropositive patient .</brief_summary>
	<brief_title>Phase 2B Dose-Ranging Study PAC113 Mouthrinse HIV Seropositive Individuals With Oral Candidiasis</brief_title>
	<detailed_description>This randomize , examiner-blinded , positive-controlled , parallel design clinical trial , feature 4 treatment arm . Forty-five ( 45 ) * HIV positive subject per treatment arm recruit 180 subject total . The study include 5 visit : screen visit , 14-day treatment phase baseline visit Day 1 , Day 7 visit , post-treatment visit 5 day last dose , follow-up visit . During screen visit subject assess study eligibility . Eligible subject randomize 1 follow treatment arm : A . 0.15 % PAC-113 mouthrinse ( 5 mL 4 time daily [ q.i.d . ] ) ; B . 0.075 % PAC-113 mouthrinse ( 5 mL q.i.d . ) ; C. 0.0375 % PAC-113 mouthrinse ( 5 mL q.i.d . ) ; D. Nystatin oral suspension ( 100,000 units/mL ; 5 mL q.i.d . ) Subjects evaluate clinically safety severity clinical sign symptom oral candidiasis baseline ( Day 1 ) , Day 7 , Day 19 ( 5 day post-treatment ) Day 28 ( follow-up visit ) . Subjects also microbiological analysis perform screening , Days 7 , 19 28 .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<criteria>Are male female 18 65 year age , inclusive Are able willing follow study procedure instruction Are able read , understand sign inform consent form Are document HIV positive Have pseudomembranous and/or erythematous oral candidiasis confirm potassium hydroxide preparation mucosal scrap Have CD4 cell count perform prior randomization within 6 week prior screen visit Have viral load perform prior randomization within 6 week prior screen visit . Both men woman active heterosexually must willing practice medically accept method birth control . Have receive systemic antifungal therapy within 14 day start study Have receive prior topical therapy oral candidiasis within 7 day start study Have concomitant fungal infection require systemic therapy Are currently receive immunosuppressive therapy ( e.g . corticosteroid ) , cancer chemotherapy Female subject pregnant ( determined positive serum urine pregnancy test ) lactating , female subject childbearing potential use hormonal barrier method birth control ( e.g. , oral parenteral contraceptive , diaphragm plus spermicide , condom ) characterize abstinent . Subjects use hormonal contraceptive must start method least 30 day prior screen examination Active substance abuse Have esophageal symptom ( dysphagia odynophagia ) unless esophageal candidiasis rule endoscopy Have life expectancy &lt; 4 week Are currently receive receive investigational agent last 30 day Have change antiretroviral therapy within 14 day prior study entry ( apply dose adjustment therapy ) Have follow laboratory abnormality : White blood cell ( WBC ) count &lt; 1,500 cells/mm3 Neutrophil granulocyte count &lt; 1,000 cells/mm3 Hemoglobin &lt; 9.0/dL Transaminases ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) bilirubin &gt; 3 time upper limit normal ( ULN ) Serum creatinine &gt; 2 time ULN Have perioral lesion ( perleche ) Have oral manifestation herpes simplex ( active disease ) , hairy leukoplakia and/or aphthous ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>oral candidiasis</keyword>
</DOC>